Pipeline
Pipeline

Jazz’s development pipeline includes the clinical development of new therapies to treat unmet medical needs, line extensions for existing products, and the generation of additional clinical data for existing products.

R&D Pipeline

Pipeline-3

Updated 08/08/2017

1 U.S. approved indication.
2 NDA submission assumes positive study outcome.
3 Evaluation of deuterated oxybate continues as part of the once-nightly development process.
4 Evaluating early stage product candidates, including recombinant pegaspargase.
t-AML = Therapy-Related Acute Myeloid Leukemia, AML-MRC = AML with Myelodysplasia-Related Changes, FDA = U.S. Food and Drug Administration, MAA = Marketing Authorization Application, ES = Excessive Sleepiness, OSA = Obstructive Sleep Apnea, NDA = New Drug Application, sNDA = Supplemental New Drug Application, VOD = Hepatic Veno-occlusive Disease, FPI = First Patient In, EDS = Excessive Daytime Sleepiness, GvHD = Graft versus Host Disease, ALL = Acute Lymphoblastic Leukemia